FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de stacks

Post-Viral Recovery

Immune Supportintermediate

83

synergie

83
Share
Pépétides

3

Moyenne journalière en mcg

2,100

Niveau

intermediate

Ajouté

May 17, 2026

Aperçu

The Post-Viral Recovery stack is designed for individuals experiencing persistent fatigue, immune dysregulation, and inflammatory symptoms following viral infections — including but not limited to long COVID, post-EBV syndromes, and chronic fatigue syndrome with viral triggers. The protocol increases Thymosin Alpha-1 frequency to 3x weekly (from the standard 2x) to provide more aggressive immune reconstitution. Ta1''s ability to restore T-cell subset ratios (CD4/CD8 balance), enhance dendritic cell maturation, and promote interferon production makes it the cornerstone of post-viral immune recovery. Clinical data from COVID-19 treatment showed Ta1 reduced mortality and improved T-cell counts in critically ill patients. LL-37 is the only human cathelicidin — an antimicrobial peptide produced by neutrophils, macrophages, and epithelial cells as a first-line defense against pathogens. Beyond direct antimicrobial activity (it disrupts bacterial and viral membranes), LL-37 modulates immune cell recruitment, promotes wound healing, and importantly, helps resolve chronic inflammation by promoting macrophage phenotype switching from M1 (pro-inflammatory) to M2 (resolving/repair). In post-viral syndromes, persistent M1-dominant inflammation drives ongoing symptoms; LL-37 may help break this cycle. BPC-157 at twice-daily dosing provides systemic anti-inflammatory support and gut healing — critical because many post-viral syndromes involve gut barrier disruption and microbial translocation that perpetuate immune activation. Its modulation of the nitric oxide system and multiple growth factor pathways creates a tissue-repair environment throughout the body. The three-peptide combination addresses post-viral recovery comprehensively: Ta1 restores immune competence, LL-37 resolves chronic inflammation and provides antimicrobial coverage, and BPC-157 repairs tissue damage and restores gut barrier function. This is classified as intermediate due to the three-compound regimen and the clinical complexity of post-viral conditions.

Protocole de dose

Thymosin Alpha-1

3x/week· subcutaneous

Lire plus sur Thymosin Alpha-1 →

1,500 mcg

par dose

LL-37

Every day· subcutaneous

Lire plus sur LL-37 →

100 mcg

par dose

BPC-157

Twice per day· subcutaneous

Lire plus sur BPC-157 →

250 mcg

par dose

Objectifs & Preuves

Post-viral fatigueImmune reconstitutionInflammationLong COVIDRecovery
Niveau d'évidence :Données humaines

Avertissements

  • LL-37 is an antimicrobial peptide with emerging research for post-viral syndromes. Limited human data outside of wound healing. Thymosin Alpha-1 remains FDA Category 2 (restricted) in the US (approved abroad as Zadaxin).

Comments

Sign in to join the discussion

Avertissement : Ce stack est soumis par la communauté et est destiné à des fins de recherche uniquement. Peptide Contacts ne vérifie pas la sécurité ou l'efficacité des stacks soumis. Consultez toujours un professionnel qualifié de la santé avant d'utiliser tout protocole de péptides.